First human dosed with cellular reprogramming drug in longevity trial
AI Summary
In a groundbreaking development, a Boston biotech firm has given the first human dose of a cellular rejuvenation drug, marking a significant step forward in the quest to tackle age-related diseases through epigenetic modification. This trial represents a leap in longevity research, potentially offering new avenues to combat the biological aging process. The implications could be huge, suggesting that extending human healthspan and improving quality of life for older adults may soon become more attainable.
Original Source
Read the full article at Washingtontimes →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.